Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats
Autor: | Megan M. Kangiser, Linda P. Dwoskin, Peter A. Crooks, Guangrong Zheng, Dustin J. Stairs |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine Agonist Reinforcement Schedule Substance-Related Disorders medicine.drug_class media_common.quotation_subject Amphetamine-Related Disorders Self Administration Pharmacology Partial agonist Article Methamphetamine Rats Sprague-Dawley 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacotherapy medicine Animals Varenicline media_common Dose-Response Relationship Drug Addiction Rats Behavior Addictive Psychiatry and Mental health 030104 developmental biology Monoamine neurotransmitter chemistry Lobeline Central Nervous System Stimulants Self-administration Reinforcement Psychology 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Behavioural Pharmacology. 29:87-97 |
ISSN: | 0955-8810 |
Popis: | Methamphetamine is a potent psychostimulant with high abuse rates. Currently, there is no Food and Drug Administration-approved pharmacotherapy for methamphetamine addiction. Ideally, a pharmacotherapy should selectively decrease methamphetamine self-administration without affecting responding for other reinforcers. One way to test this is with the use of a multiple schedule of reinforcement, in which drug and food are available in alternating components within a session. The present study evaluated GZ-793A, a vesicular monoamine transporter-2 inhibitor, and varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic acetylcholine receptors, for their ability to decrease methamphetamine and food self-administration using a multiple schedule of reinforcement. Male Sprague-Dawley rats self-administered methamphetamine (0.03 mg/kg/intravenous infusion) and food pellets under a multiple schedule of reinforcement. GZ-793A or varenicline was administered before multiple schedule sessions. GZ-793A (5 and 20 mg/kg) significantly decreased methamphetamine intake compared with saline and did not alter food-maintained responding. In contrast, varenicline decreased methamphetamine intake less specifically across time. The results suggest that vesicular monoamine transporter-2 inhibition may be a viable pharmacological target for the treatment of methamphetamine-use disorders. |
Databáze: | OpenAIRE |
Externí odkaz: |